3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Conditions
Lymphoma, Mantle-Cell
4
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Burkitt Lymphoma
2
Waldenstrom Macroglobulinemia
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia, Hairy Cell
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
27
fludarabine
19
Dexamethasone
18
pembrolizumab
12
Rituximab
12
Etoposide
11
venetoclax
10
pomalidomide
9
Gemcitabine
9
Lenalidomide
8
fludarabine phosphate
7
daratumumab
7
Bortezomib
7
glofitamab
6
carfilzomib
6
Vincristine
6
obinutuzumab
5
Temozolomide
5
Prednisone
5
Nivolumab
5
Immunotherapy, Adoptive
5
Doxorubicin
5
Cytarabine
5
Cisplatin
5
Calcium Dobesilate
5
selinexor
4
cemiplimab
4
Carboplatin
4
Azacitidine
4
zanubrutinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recurrence
×
brexucabtagene autoleucel
×
90 days
×
Clear all
NCT02625480
2026-04-09
ZUMA-4
Gilead Sciences
Phase 1/2
Completed
95 enrolled
NCT05537766
2026-03-10
ZUMA-25
Gilead Sciences
Phase 2
Terminated
19 enrolled
28 charts